| Page 59 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients

Key Points
Adult patients with hematologic malignancy and COVID-19 have a 34% risk of death, while pediatric patients have a 4% risk of death.

Patients on systemic anti-cancer therapy had a similar risk of death to patients on no treatment (RR 1.17, 95% CI 0.83-1.64).

Rogue Antibodies and Gene Mutations Explain Some Cases of Severe COVID-19

One of the many perplexing issues with COVID-19 is that it affects people so differently. That has researchers trying to explain why some folks bounce right back from the virus, or don’t even know they have it—while others become critically ill. Now, two NIH-funded studies suggest that one reason some otherwise healthy people become gravely ill may be previously unknown trouble spots in their immune systems, which hamper their ability to fight the virus.

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Author(s): 
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M
Primary Author: 
Bejanyan N
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Sep 2020

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Bone Marrow Disease(s): 

Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Author(s): 
Jan Philipp Bewersdorf, Amer M Zeidan
Primary Author: 
Jan Philipp
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Oct 2020

For most patients with higher-risk

Bone Marrow Disease(s): 

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

Author(s): 
Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M
Primary Author: 
Efficace F
Journal Title: 
Leukemia
Original Publication Date: 
Sep 2020

We aimed to compare fatigue of newly diagnosed patients with

Bone Marrow Disease(s): 

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes

Author(s): 
Nagata Y, Zhao R, Awada H, Kerr CM, Mirzaev I, Kongkiatkamon S, Nazha A, Makishima H, Radivoyevitch T, Scott JG, Sekeres MA, Hobbs BP, Maciejewski JP
Primary Author: 
Nagata Y
Journal Title: 
Blood
Original Publication Date: 
Sep 2020

Morphological interpretation is the standard in diagnosing myelodysplastic syndrome (MDS), but it has limitations, such as varying reliability in pathologic evaluation and lack of integration with genetic data. Somatic events shape morphologic features, but the complexity of morphologic and genetic changes make clear associations challenging. This article interrogates novel clinical subtypes of MDS using a machine learning technique devised to identify patterns of co-occurrence among morphologic features and genomic events.

Bone Marrow Disease(s):